mi-3

MI-3 (Menin-MLL Inhibitor) (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM).

OSMI-3 is a potent and cell-permeable inhibitor of O-GlcNAc transferase (OGT) for the study of cancer and cardiovascular disease.

CMI-392 is a dual inhibitor of 5-lipoxygenase and a receptor antagonist for platelet-activating factor (PAF) with IC50 values of 100 nM and 10 nM, respectively.

MI-389 is a PROTAC degrader that induces the degradation of receptor tyrosine kinases (RTKs), useful in leukemia research.

MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission.

JMI-346 can be used as an anti-malarial agent that inhibits the P. falciparum strains CQS (3D7) and CQR (RKL-9) growth with IC50 values of 13 μM and 33 μM. JMI-346 is a potent inhibitor of Plasmodium falciparum falcipain-2 protease (PfFP-2) [1].

Methylisothiazolinone (MI) is a powerful synthetic biocide and preservative within the group of isothiazolinones.

MI-192 is a selective HDAC2 and HDAC3 inhibitor with IC50 values of 30 nM and 16 nM, respectively. It exhibits greater selectivity for HDAC2 3 over other HDAC isomers and induces apoptosis in myeloid leukemic cells, indicating potential therapeutic use in leukemia and as an anti-stroke agent [1] [2].

Methylisothiazolinone is a powerful synthetic biocide and preservative.